Biomarkers for Alzheimer disease (AD) provide insight into disease processes and may aid clinical diagnosis for individuals with cognitive impairment. Author Stephen Salloway, MD, MS, of Brown University joins JAMA Deputy Editor Christopher Muth, MD, to discuss 2 articles and an accompanying editorial about blood biomarkers for AD and potential implications for clinical practice. Related Content: